The General Authority for Competition announced its approval for the conclusion of the economic concentration process between Al Hammadi Company for Development and Investment and Sudair Pharmaceutical Co.
Al Hammadi for Development and Investment acquired 35 percent of Sudair Pharmaceuticals’ shares.